Ontology highlight
ABSTRACT:
SUBMITTER: Kang D
PROVIDER: S-EPMC7689835 | biostudies-literature | 2020 Dec
REPOSITORIES: biostudies-literature
Kang Dongwoo D Ludwig Elizabeth E Jaworowicz David D Huang Hannah H Fiedler-Kelly Jill J Cortes Jorge J Ganguly Siddhartha S Khaled Samer S Krämer Alwin A Levis Mark M Martinelli Giovanni G Perl Alexander A Russell Nigel N Abutarif Malaz M Choi Youngsook Y Mendell Jeanne J Yin Ophelia O
Journal of clinical pharmacology 20200629 12
Quizartinib is an FMS-like tyrosine kinase 3 (FLT3) inhibitor that has shown robust clinical activity in patients with FLT3-internal tandem duplication-mutated relapsed/refractory acute myeloid leukemia (AML). This analysis evaluated the population pharmacokinetics (PK) of quizartinib and its active metabolite, AC886, in a pooled analysis of data from 649 healthy volunteers or patients with AML from 8 clinical trials including the phase 3 QuANTUM-R study. Quizartinib was given as a single dose o ...[more]